Clinical trials
High-Risk Cancer clinical trials
Below are recruiting high-risk cancer clinical trials, each written for real people, not researchers. We’re tracking 392 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06762769RecruitingPhase 2
Isatuximab and iberdomide for high-risk smoldering myeloma
This trial is testing a combination of two drugs, isatuximab and iberdomide, to help people with high-risk smoldering myeloma avoid progressing to active multiple myeloma. It aims to see if this immunotherapy approach can delay or prevent the need for stronger treatments.
LondonAges 18 years+ - NCT07452991Recruiting
Ultrasound-guided clot-busting for moderate-risk pulmonary embolism
This trial tests a procedure that uses ultrasound to guide a catheter that delivers clot-dissolving medicine directly to a blood clot in the lungs. It is for people who have a pulmonary embolism that causes some heart strain but who are not in shock.
MoscowAges 18 years+ - NCT07562503RecruitingPhase 2
Blood Test to Guide Colorectal Cancer Follow-Up Treatment
This trial tests whether a special blood test that detects cancer DNA can help doctors decide if you need additional chemotherapy after colorectal cancer surgery. The goal is to personalize treatment based on your individual risk rather than giving chemotherapy to everyone.
ShanghaiAges 18–80 - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT05893030Recruiting
Monitoring pain and sleep medicines to prevent complications after surgery
This study looks at whether closely monitoring opioid and sleep medicines during and after surgery can lower organ problems and death in older adults at high risk. If you qualify, your team will track how these medicines are given to help keep you safer in the postoperative period.
AmiensAges 75 years+ - NCT04290663RecruitingPhase 3
Radioiodine decision after thyroid surgery for intermediate-risk cancer
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Pointe à Pitre, GuadeloupeAges 18 years+ - NCT07230847Recruiting
Healing of drug-coated vs. standard stents in high-bleeding-risk patients
This trial compares two types of stents (a drug-coated stent and a standard drug-eluting stent) in people with acute coronary syndrome who also have a high risk of bleeding. It uses a special camera to look at how the artery heals one month after the stent is placed.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04945642Recruiting
Radiation combination therapy for intermediate to high-risk prostate cancer
This trial studies a combination of two radiation types—high-dose-rate brachytherapy and stereotactic body radiotherapy—to treat certain intermediate- to high-risk prostate cancers. It may help by aiming radiation closely at the prostate while also targeting the cancer from outside the body.
Los Angeles, CaliforniaAges 18 years+ - NCT06220435Recruiting
Radiation therapy for very high-risk localized prostate cancer
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
LundAges 18 years+ - NCT07231627Recruiting
Using AI to improve prostate cancer detection from MRI
This trial tests whether an artificial intelligence (AI) program can help doctors decide when a prostate biopsy is needed. It is for men who have had a prostate MRI that shows either a low-risk (PIRADS 1-2) or uncertain (PIRADS 3) spot, along with a higher-than-normal PSA level. You may qualify if you have certain risk factors like a high PSA density, suspicious digital rectal exam, or family history of prostate cancer.
Little Rock, ArkansasAges 40 years+ - NCT06087068RecruitingPhase 2
Thyroid hormone therapy after lobectomy for low-risk thyroid cancer
This trial is testing whether thyroid hormone replacement after surgery is safe for people with low-risk papillary thyroid cancer. It may help maintain normal hormone levels after part of the thyroid is removed.
Beijing, Beijing MunicipalityAges 1.5 years–70 years - NCT06725576Recruiting
Comparing microwave ablation vs. surgery for low-risk thyroid cancer
This study compares a less invasive procedure (microwave ablation) with traditional surgery for treating a small, low-risk papillary thyroid cancer. If you have a single, small tumor with certain low-risk gene changes, you might be able to avoid surgery and have a quicker recovery.
Guangzhou, GuangdongAges 18–70 - NCT06261190Enrolling by invitation
Active monitoring for low-risk thyroid cancer
This trial tests whether it is safe to avoid immediate surgery and instead monitor small thyroid cancers that are considered low-risk. If you join, doctors will check regularly to make sure the cancer does not grow or spread.
Goyang-siAges 18 years+ - NCT07046585Recruiting
Blood test for colon cancer screening
This trial tests a new blood test to screen for colorectal cancer in people at average risk. You would give a blood sample before your scheduled colonoscopy, and the results will be compared to the colonoscopy findings.
Austin, TexasAges 40 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT06582446RecruitingPhase 2
AI-Personalized Radiation for High-Risk Prostate Cancer
This trial tests a new way to plan prostate cancer treatment using artificial intelligence and advanced imaging. It’s for people with high-risk prostate cancer that hasn’t spread to lymph nodes or other parts of the body, and who have not had prior radiation to the prostate.
LimassolAges 18 years+ - NCT00913939Recruiting
MRI-guided high-dose-rate treatment for recurrent prostate cancer
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
Toronto, OntarioAges 18 years+ - NCT06711055Recruiting
Taxane plus targeted therapy for early HER2-positive breast cancer
This trial tests a taxane chemotherapy combined with a targeted therapy for women with early-stage, HER2-positive breast cancer that has not spread to lymph nodes. It aims to provide a tailored treatment based on tumor size and risk factors.
Beijing, Beijing MunicipalityAges Any age - NCT06711068Recruiting
Chemotherapy plus targeted therapy for HER2+ early breast cancer
This trial tests whether adding targeted therapy to chemotherapy after surgery can help prevent HER2-positive early breast cancer from coming back. It is for patients whose cancer has not spread to lymph nodes and who have certain tumor sizes and features.
Beijing, Beijing MunicipalityAges Any age - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT07380646RecruitingPhase 2
Leucogen to prevent low white blood cells from ribociclib in early breast cancer
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Hangzhou, ZhejiangAges 18 years+ - NCT06445114RecruitingPhase 2
Blood-Guided Chemoradiation for HPV-Positive Throat Cancer
This study tests whether a blood test that looks for circulating HPV DNA (ctDNA) can help doctors decide if you need chemotherapy after surgery for HPV-positive throat cancer. After you have surgery to remove the cancer, you receive radiation (possibly with chemotherapy) — the results of the blood test guide whether or not to add chemo.
Beverly Hills, CaliforniaAges 18 years+ - NCT07182279RecruitingPhase 1/Phase 2
Internal radiation before prostate surgery for high-risk cancer
This trial tests a treatment approach for newly diagnosed, high-risk prostate cancer. You would receive a short course of internal radiation (high-dose-rate brachytherapy) before surgery to remove your prostate. The goal is to see if this combination is safe and works better than surgery alone.
Houston, TexasAges 40 years+ - NCT06248996RecruitingPhase 3
Testing a stronger radiation schedule for large head and neck cancers
This trial tests whether giving a slightly different schedule of radiation (more frequent, smaller doses) can improve treatment for people with large head and neck cancers. It is for patients who are getting radiation as their main treatment, sometimes with chemotherapy as well.
GävleAges 18–100
Hear when a new High-Risk Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high-risk cancer?
- Yes. Clin2 currently lists 392 recruiting high-risk cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high-risk cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high-risk cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.